New Delhi – A novel antibody therapy that targets both immune cells and cancer cells has shown the ability to wipe out remaining disease in patients with multiple myeloma, based on interim data from a clinical study.
Eighteen patients received up to six treatment cycles of the bispecific antibody linvoseltamab. Highly sensitive tests revealed no detectable cancer in any participant, the results were shared at the American Society of Hematology meeting in Orlando.
These early findings suggest that linvoseltamab could spare patients from an intensive bone‑marrow transplant and its harsh chemotherapy regimen, opening a new pathway to longer‑term control.
The data also hint at a brighter overall survival outlook for those battling this condition.
“These patients received modern and effective, up‑front treatment that eliminated 90 per cent of their tumour,” said lead researcher Dickran Kazandjian of the University of Miami’s Miller School of Medicine.
“Usually, patients like these would receive high‑dose chemotherapy and transplant. Instead, we give them a treatment with the drug linvoseltamab,” Kazandjian added.
The investigators described the results as “extremely impressive” and noted that the disappearance of lingering myeloma cells signals a favorable future for patients, though the possibility of relapse remains.
Multiple myeloma originates from plasma cells—immune cells that normally produce antibodies. In cancer, these cells multiply and undermine normal blood cell production, and a definitive cure has not yet been established.
Linvoseltamab works by binding to CD3 on T cells and to BCMA on myeloma cells, physically linking the two and boosting the body’s immune assault on the cancer.
A few patients reported mild side effects, such as low white blood cell counts and upper respiratory infections, but all were considered within an acceptable safety profile.
Given its encouraging early performance, researchers hope linvoseltamab may provide more durable disease control than transplant, potentially moving toward a long‑term functional cure.
Stay informed on all the latest news, real-time breaking news updates, and follow all the important headlines in world News on Latest NewsX. Follow us on social media Facebook, Twitter(X), Gettr and subscribe our Youtube Channel.
